Related references
Note: Only part of the references are listed.Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi™): multidisciplinary perspective
Javier P. Gisbert et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Cost to Medicare of Delayed Adalimumab Biosimilar Availability
ChangWon C. Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
The Importance of Countering Biosimilar Disparagement and Misinformation
Hillel P. Cohen et al.
BIODRUGS (2020)
Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®
JongAh Joanne Lee et al.
BIOLOGICALS (2019)
Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry
Florian Fussl et al.
MABS (2019)
Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab
Nayoung Lee et al.
MABS (2019)
Era of biosimilars in rheumatology: reshaping the healthcare environment
Josef S. Smolen et al.
RMD OPEN (2019)
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Maintaining consistent quality and clinical performance of biopharmaceuticals
William C. Lamanna et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Biosimilars: Concepts and controversies
Reyes Gamez-Belmonte et al.
PHARMACOLOGICAL RESEARCH (2018)
Biopharmaceutical benchmarks 2018
Gary Walsh
NATURE BIOTECHNOLOGY (2018)
Batch-to-batch N-glycosylation study of infliximab, trastuzumab and bevacizumab, and stability study of bevacizumab
Ana Planinc et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2017)
A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers
D. Shin et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
Seokkyun Kim et al.
MABS (2017)
The process defines the product: what really matters in biosimilar design and production?
Arnold G. Vulto et al.
RHEUMATOLOGY (2017)
Considerations of of critical quality attributes in the analytical comparability assessment of biosimilar products
Ohseok Kwon et al.
BIOLOGICALS (2017)
Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents
Balazs Vezer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins
Fabian Higel et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2016)
Drift, Evolution, and Divergence in Biologics and Biosimilars Manufacturing
Sundar Ramanan et al.
BIODRUGS (2014)
Biosimilars in rheumatology: the wind of change
Christian K. Schneider
ANNALS OF THE RHEUMATIC DISEASES (2013)
Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies
Yi Du et al.
MABS (2012)
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Martin Schiestl et al.
NATURE BIOTECHNOLOGY (2011)
Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods
J. Vlasak et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Heterogeneity of monoclonal antibodies
Hongcheng Liu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Post-translational modifications in the context of therapeutic proteins
Gary Walsh et al.
NATURE BIOTECHNOLOGY (2006)
Share Paper
